Adjunctive Probio-X Treatment Enhances the Therapeutic Effect of a Conventional Drug in Managing Type 2 Diabetes Mellitus by Promoting Short-Chain Fatty Acid-Producing Bacteria and Bile Acid Pathways

• DOI: 10.1128/msystems.01300-22
• Publication Date: 2023-01-23T14:01:48Z
• Authors: Ye Chen; Xin Shen; Teng Ma; Xia Yu; Lai-Yu Kwok; Yalin Li; Zhihong Sun; Dongmei Li; Heping Zhang
• Keywords: bile acids; 0301 basic medicine; Bacteria; type 2 diabetes mellitus; short-chain fatty acids; gut microbiome; Fatty Acids, Volatile; Microbiology; QR1-502; Metformin; 3. Good health; Bile Acids and Salts; 03 medical and health sciences; probiotics; Diabetes Mellitus, Type 2; Humans; metformin; Research Article

Metformin is a common drug for the management of type 2 diabetes mellitus; however, it causes various adverse gastrointestinal effects, especially after prolonged treatment. It thus interest to identify an adjuvant treatment that synergizes with efficacy metformin while mitigating its effects. Since previous evidence supports gut microbiota target metformin, this study investigated beneficial effect and mechanism coadministration probiotics in mellitus by conducting 3-month randomized, double-blind, placebo-controlled clinical trial (n = 27 21 probiotic placebo groups, respectively, who completed trial). Clinical results showed significantly reduced glycated hemoglobin compared taken alone (P < 0.05). Metagenomic metabolomic analyses increased abundance short-chain fatty acid (SCFA)-producing bacteria bile acids. Significantly or marginally more acids related metabolites were detected group than postintervention. Taken together, our synergized hypoglycemic patients mellitus, which was likely through modulating microbiome and, subsequently, SCFA metabolism. Our findings support cotreatment mellitus. IMPORTANCE variable We found Probio-X may promote SCFA-producing levels specific acids, increasing secretion hormones ultimately improving glucose homeostasis.